{ "@context": "https://clearank.com/llms.txt", "@type": "clearank:AssetAnalysis", "url": "https://clearank.com/stock/zimmer-biomet-zbh/", "dataUrl": "https://clearank.com/stock/zimmer-biomet-zbh/data.json", "title": "Zimmer Biomet (ZBH) Stock Forecast & Price Target (2026)", "description": "ZBH stock forecast 2026: is Zimmer Biomet a buy? Analysts' median price target is $105 (9% upside). CleaRank Financial AI rates it Buy, 70/100. Updated daily.", "headline": "Zimmer Biomet Holdings Inc. (ZBH)", "published": "2026-10-25T15:17:48.422357+00:00", "modified": "2026-10-27T20:57:08.576+00:00", "generated": "2026-10-28T03:26:59.045Z", "language": "en-US", "publisher": { "name": "CleaRank", "url": "https://clearank.com/" }, "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by Jacob Bakshi, Senior Market Strategist; prices delayed up to 15 minutes.", "asset": { "ticker": "ZBH", "name": "Zimmer Biomet Holdings Inc.", "type": "Common Stock", "exchange": "NYSE", "currency": "USD", "sector": "Healthcare", "industry": "Medical Devices", "country": "United States", "website": "https://www.zimmerbiomet.com" }, "quote": { "price": 96.08, "previousClose": 97.44, "change": -1.36, "changePercent": -1.4, "open": 97.22, "high": 97.22, "low": 95.23, "volume": 89188, "averageVolume": 1650619, "marketCap": 18326077159, "fiftyTwoWeekHigh": 103.7, "fiftyTwoWeekLow": 79.12, "marketOpen": false, "asOf": "2026-10-27T20:57:08.000Z" }, "statistics": { "pe": 22.4, "eps": 4.29, "dividendYield": 0.009991673605328892, "beta": 0.485, "priceToSales": 2.1538, "priceToBook": 1.4745139, "revenueTtm": 8508800000, "grossMargin": 0.7080845199816261, "returnOnEquity": 0.06413 }, "technicals": { "rsi": 55.47, "macd": 1.09, "sma50": 95.06, "sma200": 91.53, "rsiSignal": "Neutral", "trend": "Bullish", "pricePosition": "Bullish", "macdSignal": "Bullish", "rating": "Bullish" }, "analysis": { "rating": "Buy", "score": 70, "consensus": "Buy", "fairValue": null, "analystTarget": 105, "analystCount": 27, "wallStreetConsensus": "Hold", "generatedAt": "2026-10-27T20:57:08.000Z", "priceAtAnalysis": 96.08, "volatility": { "daily": 1.83, "risk": "standard" } }, "tradePlan": { "bias": "Bullish", "conservativeEntry": 94.16, "aggressiveEntry": 96.08, "stopLoss": 91.21, "stopLossPercent": 3.13, "targets": [ 98.87, 103.57, 108.28 ] }, "projections": { "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets", "years": [ { "year": 2027, "downside10th": 67.68, "base": 98.06, "upside90th": 142.08 }, { "year": 2028, "downside10th": 59.25, "base": 100.09, "upside90th": 169.09 }, { "year": 2029, "downside10th": 53.75, "base": 102.15, "upside90th": 194.16 }, { "year": 2030, "downside10th": 49.67, "base": 104.26, "upside90th": 218.87 } ] }, "faqCount": 10, "atAGlance": { "asOf": "October 27, 2026", "rating": "Buy", "score": 70, "evidence": [ { "label": "Trend", "text": "Up: the price is above both its 50- and 200-day moving averages ($95.06 and $91.53)." }, { "label": "Earnings", "text": "ZBH beat estimates in 6 of its last 7 quarters, yet fell the next day after 3 of those beats." }, { "label": "Insiders", "text": "Insiders sold $2.2M and made no open-market purchases over the last 18 months." }, { "label": "Valuation", "text": "P/E of 22.4 against 31.9 for the Healthcare sector: a discount to peers (-30%)." } ] }, "figures": { "asOf": "October 27, 2026", "earningsReaction": { "quarters": 7, "beats": 6, "fellFirstSessionAfterBeat": 3, "latestReport": "Aug 5, 2026", "latestSurprisePercent": 2.99, "latestFirstSessionMovePercent": -0.99 }, "insiders": { "windowMonths": 18, "soldValue": 2187856, "boughtValue": 0, "sales": 10, "purchases": 0, "note": "open-market transactions only; grants and option exercises excluded" }, "drawdown": { "years": 10, "worstFallPercent": -51.53, "peak": "April 2021", "trough": "May 2026", "recoveredBy": null, "recoveryMonths": null, "belowThatPeakNowPercent": -41.17, "fromHighNowPercent": -41.17, "oneYearHoldsPositivePercent": 48, "dividendsReinvested": true }, "seasonality": { "years": 10, "bestMonth": { "month": "Jul", "averagePercent": 5.55, "upYearsPercent": 70 }, "worstMonth": { "month": "May", "averagePercent": -3.82, "upYearsPercent": 10 } }, "correlations": null, "analystTargets": { "analysts": 27, "low": 93, "median": 105, "high": 130, "mean": 106.9, "buy": 8, "hold": 19, "sell": 0 }, "dividend": { "yieldPercent": 0.9992, "annualPerShare": 0.96 }, "simulation": { "year": 2030, "base": 104.26, "percentile10": 49.67, "percentile90": 218.87, "note": "Monte Carlo simulation outcomes, not price targets" } }, "sources": [ "TwelveData", "Wall Street consensus" ], "sections": [ { "id": "ch-overview", "title": "ZBH stock forecast today", "text": [ "Where ZBH stands today, and what CleaRank Financial AI makes of it.", "Zimmer Biomet Holdings Inc. (ZBH): Buy, 70/100 on CleaRank's AI score.", "Figures as of October 27, 2026.", "CleaRank rates Zimmer Biomet Holdings Inc. (ZBH) Buy, with a model score of 70/100. Valuation lifts the score most: the P/E of 22.40 is 29.8% below the sector median (a discount to peers) and the P/S of 2.15 is 36.8% below the sector median. Revenue growth holds it back most: revenue grew 4.80%, 3.3 percentage points slower than the sector median. The trend is up: ZBH trades 1.08% above its 50-day average of $95.06 and 4.97% above its 200-day average of $91.53. Over the past year the price fell 6.83%.", "Figures we compute ourselves from ZBH's own price, earnings and insider-filing history. Tap one to see it in context." ], "lists": { "ZBH at a glance": [ "Trend Up: the price is above both its 50- and 200-day moving averages ($95.06 and $91.53).", "Earnings ZBH beat estimates in 6 of the 7 reports in our data, yet fell the next day after 3 of those beats.", "Insiders Insiders sold $2.2M and made no open-market purchases over the last 18 months.", "Valuation P/E of 22.4 against 31.9 for the Healthcare sector: a discount to peers (-30%)." ] } }, { "id": "ch-price", "title": "ZBH stock price and trading", "text": [ "The chart, today's range and how far the price has moved over each period.", "Pick a period: each tab shows how far ZBH has moved over it, to the last close.", "Where ZBH sits inside today's range and its 52-week range." ], "lists": { "items": [ "Price above its 50-day average › The price of $96.08 is 1.1% above the 50-day simple moving average of $95.06.", "Price above its 200-day average › The price is 5.0% above the 200-day simple moving average of $91.53.", "50-day average above the 200-day › The 50-day average ($95.06) is 3.8% above the 200-day average ($91.53), the arrangement of a rising longer-term trend.", "In the upper half of its 52-week range › The price sits at 69% of its 52-week range, between $79.12 and $103.70." ] } }, { "id": "ch-fundamentals", "title": "ZBH fundamentals and valuation", "text": [ "Valuation against the sector, and the revenue and earnings behind it.", "The headline figures for ZBH.", "As of October 27, 2026, ZBH trades at $96.08, with a market value of $18.33B, a P/E ratio of 22.40 and a dividend yield of 1.00%.", "CleaRank Financial AI's reading of ZBH's valuation, growth and risks.", "Against the 31.9 median P/E of Healthcare stocks, ZBH's P/E of 22.40 is 29.8% below that median, which counts as a discount to peers. ZBH trades at 2.15 times its sales, 36.8% below the sector median of 3.4. ZBH has a market capitalisation of $18.3B and trailing earnings of $4.29 a share. With revenue growth of 4.80%, ZBH is 3.3 percentage points slower than the sector median of 8.1%. The business earns a net margin of 9.48% and an operating margin of 17.96% and a return on equity of 6.41%, below the sector median of 7.3%. The balance sheet and payout round out the picture, with debt-to-equity of 0.60 and a trailing dividend yield of 1.00% ($0.96 a share a year).", "The August 5, 2026 report delivered adjusted EPS of $2.07, which topped the $2.01 analyst estimate by 2.99%. Even so, the share price dropped 0.99% in the following session. ZBH has topped the EPS estimate in 6 of the 7 reports in our data, yet those beats have not reliably lifted the shares: the stock fell the next session after 3 of them. For this fiscal year, analysts average an EPS estimate of $8.54, growth of 4.1%, and $9.05 for next year, which would be growth of 6.1%.", "ZBH typically moves about 1.83% in a day, and its beta against the S&P 500 is 0.49. Over the last 18 months insiders sold $2.2M of stock and purchased none on the open market. Such sales are frequently scheduled ahead of time, so they tell an investor less than buying would.", "How ZBH compares with the median Healthcare stock CleaRank tracks.", "Price to earnings vs sector: ZBH trades at a notable discount to sector peers (-30%), which may indicate undervaluation or specific company headwinds.", "Return vs XLV: Since May 14, 2025, ZBH has gained 2.2% against a gain of 39.2% for XLV.", "ZBH and the Healthcare sector fund over the same days.", "How much ZBH sells, and how much of it becomes profit.", "Revenue growth: Revenue grew 7.2% in FY2025 to $8.2B, from $7.7B a year earlier.", "Profit margin: The net margin was 8.6% in FY2025, down from 11.8% the year before.", "Profitable: ZBH earned $705M in FY2025.", "Did ZBH beat what analysts expected, and how did the stock react?", "Earnings record: ZBH beat the analyst estimate in 6 of the 7 reports in our data.", "Market reaction: The stock fell in the first session after 3 of those 6 beats, so a beat has not been enough on its own.", "As of October 27, 2026, ZBH has beaten the analyst EPS estimate in 6 of the 7 reports in our data and fell in the first trading session after 3 of those beats; its latest report, on August 5, 2026, came in 2.99% above the estimate and the stock moved -0.99% in the first session.", "The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate." ], "tables": [ { "caption": "ZBH earnings surprises and the stock's reaction", "columns": [ "Report", "Estimate", "Actual", "Surprise", "First sessionDay 1", "5 sessionsDay 5" ], "rows": [ { "label": "Aug 5, 2026after close", "cells": [ "$2.01", "$2.07", "+2.99%", "-0.99%", "-0.28%" ] }, { "label": "Apr 28, 2026after close", "cells": [ "$1.86", "$2.09", "+12.37%", "-3.30%", "+0.25%" ] }, { "label": "Nov 5, 2025after close", "cells": [ "$1.87", "$1.90", "+1.60%", "+1.10%", "+2.83%" ] }, { "label": "Aug 7, 2025after close", "cells": [ "$1.98", "$2.07", "+4.55%", "+0.84%", "+3.75%" ] }, { "label": "May 5, 2025after close", "cells": [ "$1.77", "$1.81", "+2.26%", "+1.98%", "+8.55%" ] }, { "label": "Feb 6, 2025after close", "cells": [ "$2.29", "$2.31", "+0.87%", "-1.71%", "-2.71%" ] }, { "label": "Oct 30, 2024after close", "cells": [ "$1.74", "$1.74", "+0.00%", "-2.63%", "+0.33%" ] } ] } ], "lists": { "items": [ "P/E below the sector median › The trailing P/E of 22.40 is 29.8% below the Healthcare median of 31.9.", "P/S below the sector median › The price-to-sales ratio of 2.15 is 36.7% below the sector median of 3.4.", "Profitable over the last 12 months › Net income over the last 12 months was $806.7M on revenue of $8.5B, a net margin of 9.5%.", "Beat estimates in most recent reports › ZBH beat the EPS estimate in 6 of the 7 reports in our data.", "Pays a dividend › The trailing dividend yield is 1.00%, or $0.96 a share a year." ] } }, { "id": "ch-analysis", "title": "ZBH AI analysis and technical indicators", "text": [ "CleaRank's score and reasoning, the indicators behind it, and what the price moves with.", "The score, the reasoning behind it, and what could move the price next.", "ZBH, the company also known as Zimmer Biomet Holdings Inc., changed hands at $96.08 and sits above both its key moving averages. The price is 1.08% above its 50-day average of $95.06 and 4.97% above its 200-day average of $91.53. The 50-day average is 3.85% above the 200-day, a configuration that backs up the upward move. Inside its 52-week range of $79.12 to $103.70, the stock stands at 69% of the way up, and the price is 7.35% below the high. Recent gains sit against a weaker longer record: the price rose 5.54% over the past month, rose 0.34% over the past three months and fell 6.83% over the past year. The 14-day RSI of 55.5 is in the neutral zone, and the MACD line is positive.", "Argus Research kept its Buy rating on October 22, 2026.", "The August 5, 2026 report beat the EPS estimate by 2.99%, and the share price fell 0.99% in the first session after it.", "Barclays started coverage at Equal-Weight on October 7, 2026.", "ZBH's uptrend depends on the price holding above its 50-day average at $95.06 and its 200-day average at $91.53. A close below the 50-day would be the first sign of that trend weakening. If the price pulls back, the 50-day SMA at $95.06 is the first level it would meet. Overhead, the next level for ZBH is the 52-week high at $103.70. The 14-day RSI reads 55.5, which sits in neutral territory between 40 and 60.", "Momentum and trend for ZBH, from its daily closes.", "As of October 27, 2026, with ZBH at $96.08, its 14-day RSI is 55.5 (neutral territory), its 50-day simple moving average is $95.06 and its 200-day is $91.53.", "Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these", "Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.", "As of October 27, 2026, ZBH's 1-year correlation of daily returns is +0.15 with S&P 500 (SPY), +0.02 with Nasdaq 100 (QQQ), -0.05 with Bitcoin (BTC) and -0.01 with gold (XAU)." ], "lists": { "items": [ "RSI Neutral", "SMA cross Bullish", "Price vs SMA Bullish", "MACD Bullish" ] } }, { "id": "ch-street", "title": "ZBH price target and analyst forecast", "text": [ "The analysts' target range and how their ratings split.", "As of October 27, 2026, 27 Wall Street analysts cover ZBH: 8 rate it a buy or strong buy, 19 a hold and 0 a sell or strong sell. Their 12-month price targets range from $93.00 to $130.00. The median ZBH price target is $105.00, 9.3% above the price of $96.08.", "Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank." ], "tables": [ { "caption": "Recent analyst rating actions on ZBH", "columns": [ "Date", "Firm", "Action", "Rating" ], "rows": [ { "label": "Oct 22, 2026", "cells": [ "Argus Research", "Reiterates", "Buy" ] }, { "label": "Oct 7, 2026", "cells": [ "Barclays", "Initiates", "Equal-Weight" ] }, { "label": "Aug 10, 2026", "cells": [ "Canaccord Genuity", "Maintains", "Hold" ] }, { "label": "Aug 7, 2026", "cells": [ "Truist Securities", "Maintains", "Hold" ] }, { "label": "Aug 6, 2026", "cells": [ "RBC Capital", "Maintains", "Outperform" ] }, { "label": "Aug 6, 2026", "cells": [ "Bernstein", "Maintains", "Market Perform" ] } ] } ], "lists": { "items": [ "Most analysts rate it a buy › 8 of 27 analysts rate it a buy or strong buy, 19 a hold and 0 a sell.", "Median target above the price › The median 12-month target of $105.00 is 9.3% above the price.", "More buy ratings than three months ago › 8 of 27 rate it a buy now, against 9 of 27 three months ago." ] } }, { "id": "ch-plan", "title": "ZBH trade plan: entry, stop loss and targets", "text": [ "Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.", "Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.", "Lower risk, wait for pullback", "Higher risk, immediate entry", "These levels come from ZBH's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.", "Would this ZBH plan have made money the last ten times?", "Your entry, stop and targets are set above. Replay them against ZBH's own history and count how often the target hit before the stop.", "How much ZBH tends to move, against the market and on its own." ], "lists": { "items": [ "Wins vs stops", "Best exit", "Max drawdown" ] }, "links": [ { "text": "Position Size", "url": "https://clearank.com/tools/position-size-calculator/" }, { "text": "Stop Loss", "url": "https://clearank.com/tools/stop-loss-calculator/" }, { "text": "Risk/Reward", "url": "https://clearank.com/tools/risk-reward-calculator/" }, { "text": "P&L Calculator", "url": "https://clearank.com/tools/profit-loss-calculator/" }, { "text": "Trailing Stop", "url": "https://clearank.com/tools/trailing-stop-calculator/" }, { "text": "Fibonacci", "url": "https://clearank.com/tools/fibonacci-calculator/" }, { "text": "Pivot Points", "url": "https://clearank.com/tools/pivot-point-calculator/" }, { "text": "Win Rate", "url": "https://clearank.com/tools/breakeven-win-rate-calculator/" }, { "text": "Expectancy", "url": "https://clearank.com/tools/trade-expectancy-calculator/" }, { "text": "Replay this plan on ZBHStart free trial · $0 today", "url": "https://trade.clearank.com/portfolio/demo?utm_source=clearank&utm_medium=cta&utm_campaign=asset_plan&utm_content=trial7" } ] }, { "id": "ch-risk", "title": "ZBH price history and drawdowns", "text": [ "ZBH's worst falls and recoveries, what $10,000 became, and which months have been kind to it.", "As of October 27, 2026, ZBH's worst peak-to-trough fall over the last 10 years with dividends reinvested was -51.5% (April 2021 to May 2026); it is still 41.2% below that peak, and 48% of 1-year holding periods ended with a gain.", "From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.", "What $10,000 put into ZBH in October 2016 is worth now, against the same amount in the S&P 500.", "Against the market: ZBH trailed the S&P 500 over this period: $9,011.89 against $42,015.", "A $10,000 investment in ZBH in October 2016 would be worth about $9,012 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).", "Which calendar months have been kind to ZBH, and which have not.", "Strongest month, July: an average of +5.55%, up in 7 of 10 years.", "Weakest month, May: an average of -3.82%, up in 1 of 10 years.", "This month, October: has averaged -1.50%, up in 4 of 9 years. Past seasonality does not repeat on schedule.", "Over the last 10 years, ZBH's strongest calendar month has been July (average +5.55%, up in 7 of 10 years) and its weakest May (average -3.82%, up in 1 of 10 years).", "Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included." ], "lists": { "items": [ "Average daily move under 2% › The price has moved 1.83% on an average day (30-day standard deviation of daily returns).", "Recovered from its worst fall › The worst fall was 51.5%, from April 2021 to May 2026; the price is still 41.2% below that peak.", "Most 1-year holds ended higher › 48% of 1-year holding periods in the last 10 years ended with a gain.", "Beat the S&P 500 since the chart begins › $10,000 invested in October 2016 is now worth $9,012, against $42,015 in the S&P 500 (SPY)." ] } }, { "id": "ch-scenarios", "title": "ZBH stock price prediction 2030", "text": [ "Thousands of simulated paths from the price history. A range of outcomes, not a forecast.", "Thousands of simulated paths for $10,000 in ZBH, from its own past volatility. The shaded area holds 80% of them.", "CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in ZBH today could grow to about $10,852 by 2030 in the base case, with a 90th-percentile outcome near $22,780 and a 10th-percentile outcome around $5,169. The simulation models price only; at today's 1.00% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.", "The same simulation in share prices, year by year.", "CleaRank's simulation projects a price near $104 for ZBH by 2030 in the base case, from $96.08 today (1.1x over 4 years). The 10th-percentile path ends near $49.67. These are outcomes of a Monte Carlo simulation run on ZBH's historical return distribution, not price targets, and they assume no dividends are reinvested.", "Method: a lognormal simulation of ZBH's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works", "What would ZBH do to your portfolio?", "Add it to what you already hold. Ten-year backtest, the drawdown it brings, and how much of it is just the S&P in disguise." ], "tables": [ { "caption": "ZBH simulated price paths by year", "columns": [ "Year", "10th percentile", "Base case", "90th percentile", "range base today" ], "rows": [ { "label": "2027", "cells": [ "$67.68", "$98.06", "$142", "" ] }, { "label": "2028", "cells": [ "$59.25", "$100", "$169", "" ] }, { "label": "2029", "cells": [ "$53.75", "$102", "$194", "" ] }, { "label": "2030", "cells": [ "$49.67", "$104", "$219", "" ] } ] } ], "lists": { "items": [ "10-year backtest", "Drawdown added", "Correlation" ] }, "links": [ { "text": "Backtest my portfolio with ZBHStart free trial · $0 today", "url": "https://trade.clearank.com/portfolio/demo?utm_source=clearank&utm_medium=cta&utm_campaign=asset_longterm&utm_content=trial7" } ] }, { "id": "ch-insiders", "title": "ZBH insider trading", "text": [ "What the people running the company have bought and sold.", "Shares the company's directors and officers bought and sold, from their own filings.", "Open-market purchases above the line, sales below.", "Net insider selling: No insider bought ZBH shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.", "As of October 27, 2026, ZBH insiders reported 10 open-market sales worth $2.2M and no open-market purchases over the last 18 months; grants and option exercises are not counted.", "Source: TwelveData, from SEC Form 4 filings" ], "tables": [ { "caption": "Insider transactions in ZBH", "columns": [ "Date", "Insider", "Type", "Shares", "Value" ], "rows": [ { "label": "Oct 1, 2026", "cells": [ "Gary Craig Campbell Officer", "Grant", "3.6K", "-" ] }, { "label": "Sep 11, 2026", "cells": [ "Kevin R Thornal Officer", "Sell", "5.7K", "$529.0K" ] }, { "label": "Sep 4, 2026", "cells": [ "Chad F Phipps Officer", "Sell", "3.0K", "$295.1K" ] }, { "label": "Jul 31, 2026", "cells": [ "Kevin R Thornal Officer", "Grant", "10.0K", "-" ] }, { "label": "May 29, 2026", "cells": [ "Sang Yi Officer", "Sell", "5.0K", "$413.2K" ] }, { "label": "Apr 1, 2026", "cells": [ "Jehanzeb Noor Officer", "Grant", "6.6K", "-" ] }, { "label": "Mar 12, 2026", "cells": [ "Lori Winkler Officer", "Sell", "2.7K", "$250.8K" ] }, { "label": "Mar 6, 2026", "cells": [ "Chad F Phipps Officer", "Grant", "6.8K", "-" ] }, { "label": "Mar 6, 2026", "cells": [ "Paul A Stellato Officer", "Grant", "2.0K", "-" ] }, { "label": "Mar 6, 2026", "cells": [ "Ivan Tornos Chief Executive Officer", "Grant", "34.7K", "-" ] }, { "label": "Mar 6, 2026", "cells": [ "Suketu P Upadhyay Chief Financial Officer", "Grant", "14.8K", "-" ] }, { "label": "Mar 6, 2026", "cells": [ "Zuilen Wilfred Van Officer", "Grant", "7.0K", "-" ] }, { "label": "Mar 6, 2026", "cells": [ "Lori Winkler Officer", "Grant", "5.6K", "-" ] }, { "label": "Mar 6, 2026", "cells": [ "Sang Yi Officer", "Grant", "9.4K", "-" ] }, { "label": "Feb 25, 2026", "cells": [ "Chad F Phipps Officer", "Grant", "2.6K", "-" ] }, { "label": "Feb 25, 2026", "cells": [ "Paul A Stellato Officer", "Grant", "820", "-" ] }, { "label": "Feb 25, 2026", "cells": [ "Ivan Tornos Chief Executive Officer", "Grant", "19.1K", "-" ] }, { "label": "Feb 25, 2026", "cells": [ "Suketu P Upadhyay Chief Financial Officer", "Grant", "6.4K", "-" ] }, { "label": "Feb 25, 2026", "cells": [ "Zuilen Wilfred Van Officer", "Grant", "3.2K", "-" ] }, { "label": "Feb 25, 2026", "cells": [ "Lori Winkler Officer", "Grant", "2.3K", "-" ] }, { "label": "Feb 25, 2026", "cells": [ "Sang Yi Officer", "Grant", "2.8K", "-" ] }, { "label": "Feb 20, 2026", "cells": [ "Chad F Phipps Officer", "Grant", "2.2K", "-" ] }, { "label": "Feb 20, 2026", "cells": [ "Paul A Stellato Officer", "Grant", "701", "-" ] }, { "label": "Feb 20, 2026", "cells": [ "Ivan Tornos Chief Executive Officer", "Grant", "16.0K", "-" ] }, { "label": "Feb 20, 2026", "cells": [ "Suketu P Upadhyay Chief Financial Officer", "Grant", "5.4K", "-" ] }, { "label": "Feb 20, 2026", "cells": [ "Zuilen Wilfred Van Officer", "Grant", "2.5K", "-" ] }, { "label": "Feb 20, 2026", "cells": [ "Lori Winkler Officer", "Grant", "1.8K", "-" ] }, { "label": "Feb 20, 2026", "cells": [ "Sang Yi Officer", "Grant", "2.4K", "-" ] }, { "label": "Feb 12, 2026", "cells": [ "Sang Yi Officer", "Sell", "1.0K", "$96.5K" ] }, { "label": "Nov 28, 2025", "cells": [ "Lori Winkler Officer", "Grant", "179", "-" ] }, { "label": "Nov 10, 2025", "cells": [ "Suketu P Upadhyay Chief Financial Officer", "Grant", "10.6K", "-" ] }, { "label": "Sep 11, 2025", "cells": [ "Sang Yi Officer", "Sell", "1.2K", "$124.3K" ] }, { "label": "Sep 8, 2025", "cells": [ "Lori Winkler Officer", "Sell", "1.5K", "$156.2K" ] }, { "label": "Aug 29, 2025", "cells": [ "Paul A Stellato Officer", "Grant", "1.3K", "-" ] }, { "label": "Aug 18, 2025", "cells": [ "Lori Winkler Officer", "Sell", "1.5K", "$153.7K" ] }, { "label": "Jul 1, 2025", "cells": [ "Zuilen Wilfred Van Officer", "Grant", "2.6K", "-" ] }, { "label": "Jun 13, 2025", "cells": [ "Sang Yi Officer", "Sell", "800", "$74.0K" ] }, { "label": "Jun 11, 2025", "cells": [ "Sang Yi Officer", "Sell", "1.0K", "$95.0K" ] }, { "label": "May 30, 2025", "cells": [ "Paul A Stellato Officer", "Grant", "626", "-" ] } ] } ], "links": [ { "text": "SEC Form 4 filings", "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Zimmer%20Biomet%20Holdings%20Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany" } ] }, { "id": "ch-faq", "title": "ZBH stock forecast: questions people ask", "text": [ "Answered from the figures on this page, as of October 27, 2026." ] }, { "id": "ch-related", "title": "Compare ZBH with similar assets", "text": [ "Assets people compare with this one." ], "links": [ { "text": "PFE Pfizer Inc NYSE $29.79 -0.80%", "url": "https://clearank.com/stock/pfizer-pfe/" }, { "text": "BDX Becton, Dickinson and Company NYSE $194.95 -0.73%", "url": "https://clearank.com/stock/bdx-stock-analysis/" }, { "text": "BIIB Biogen Inc. NASDAQ $252.26 +0.63%", "url": "https://clearank.com/stock/biib-stock-analysis/" }, { "text": "MRK Merck & Co Inc NYSE $141.82 +0.86%", "url": "https://clearank.com/stock/merck-mrk/" }, { "text": "LLY Eli Lilly & Co NYSE $1,281.91 +0.22%", "url": "https://clearank.com/stock/eli-lilly-lly/" }, { "text": "NTRA Natera, Inc. NASDAQ $410.82 +1.46%", "url": "https://clearank.com/stock/natera-ntra/" }, { "text": "TLRY Tilray Brands Inc. NASDAQ $2.72 -3.20%", "url": "https://clearank.com/stock/tilray-brands-tlry/" }, { "text": "DHR Danaher Corp. NYSE $232.97 +1.07%", "url": "https://clearank.com/stock/dhr-stock-analysis/" }, { "text": "SNPS vs CDNS Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/snps-vs-cdns/" }, { "text": "COP vs OXY Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/cop-vs-oxy/" }, { "text": "XAU/USD vs XPT/USD Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/gold-vs-platinum/" } ] } ], "faq": [ { "question": "Is Zimmer Biomet Holdings Inc. (ZBH) a buy right now?", "answer": "A score of 70/100 gives ZBH its Buy rating. Valuation carries the score: the P/E of 22.40 is 29.8% below the sector median (a discount to peers) and the P/S of 2.15 is 36.8% below the sector median. Revenue growth holds the score back, because revenue grew 4.80%, 3.3 percentage points slower than the sector median. This describes the data on this page and is not a personal recommendation." }, { "question": "How has Zimmer Biomet Holdings Inc. (ZBH) performed over the past year?", "answer": "Over the past year the price fell 6.83%. Over shorter periods it rose 0.34% in three months and rose 5.54% in the past month. It now trades 7.35% below its 52-week high of $103.70." }, { "question": "What are the key price levels for ZBH?", "answer": "The nearest level above the price is the 52-week high at $103.70. Going down, the first supports are the 50-day SMA at $95.06 and the 20-day EMA at $94.48." }, { "question": "Is ZBH expensive compared with Healthcare stocks?", "answer": "ZBH's trailing P/E of 22.40 is 29.8% below the Healthcare median of 31.9, a level the peer comparison on this page labels a discount to peers. Its price-to-sales ratio of 2.15 is 36.8% below the sector median of 3.4. These medians are drawn from 44 stocks across the entire sector, not just direct competitors." }, { "question": "Does ZBH pay a dividend?", "answer": "It does. ZBH pays a trailing dividend yield of 1.00%, which works out to $0.96 per share each year. Yield is calculated by dividing the dividend by the share price, so it moves whenever either of those moves." }, { "question": "What do Wall Street analysts think of ZBH?", "answer": "Of the 27 analysts covering ZBH, 8 rate it a buy, 19 rate it a hold, and none rate it a sell. Their median 12-month price target is $105.00, which is 9.3% above the current price." }, { "question": "How often has ZBH beaten earnings estimates?", "answer": "ZBH beat the EPS estimate in 6 of the 7 reports in our data; the share price fell in the first session after 3 of those 6 beats." }, { "question": "How volatile is ZBH?", "answer": "On an average day, ZBH's price moves 1.83%, based on the 30-day standard deviation of daily returns. Its beta against the S&P 500 is 0.49." }, { "question": "Are ZBH insiders buying or selling?", "answer": "Across the last 18 months, insiders unloaded $2.2M of shares and made no open-market purchases. Such sales are often arranged beforehand or tied to tax due on vesting shares, which makes them less telling than purchases." }, { "question": "What is the 52-week range of ZBH?", "answer": "Over the past 52 weeks, ZBH has moved between $79.12 and $103.70. At $96.08, the stock sits at 69% of that range, 21.44% above the low and 7.35% below the high." } ], "related": { "peopleAlsoWatch": [ { "ticker": "PFE", "name": "Pfizer Inc NYSE", "price": "$29.79", "change": "-0.80%", "url": "https://clearank.com/stock/pfizer-pfe/" }, { "ticker": "BDX", "name": "Becton, Dickinson and Company NYSE", "price": "$194.95", "change": "-0.73%", "url": "https://clearank.com/stock/bdx-stock-analysis/" }, { "ticker": "BIIB", "name": "Biogen Inc. NASDAQ", "price": "$252.26", "change": "+0.63%", "url": "https://clearank.com/stock/biib-stock-analysis/" }, { "ticker": "MRK", "name": "Merck & Co Inc NYSE", "price": "$141.82", "change": "+0.86%", "url": "https://clearank.com/stock/merck-mrk/" }, { "ticker": "LLY", "name": "Eli Lilly & Co NYSE", "price": "$1,281.91", "change": "+0.22%", "url": "https://clearank.com/stock/eli-lilly-lly/" }, { "ticker": "NTRA", "name": "Natera, Inc. NASDAQ", "price": "$410.82", "change": "+1.46%", "url": "https://clearank.com/stock/natera-ntra/" }, { "ticker": "TLRY", "name": "Tilray Brands Inc. NASDAQ", "price": "$2.72", "change": "-3.20%", "url": "https://clearank.com/stock/tilray-brands-tlry/" }, { "ticker": "DHR", "name": "Danaher Corp. NYSE", "price": "$232.97", "change": "+1.07%", "url": "https://clearank.com/stock/dhr-stock-analysis/" } ], "comparisons": [ { "ticker": "SNPS vs CDNS Comparison", "name": "", "url": "https://clearank.com/compare/snps-vs-cdns/" }, { "ticker": "COP vs OXY Comparison", "name": "", "url": "https://clearank.com/compare/cop-vs-oxy/" }, { "ticker": "XAU/USD vs XPT/USD Comparison", "name": "", "url": "https://clearank.com/compare/gold-vs-platinum/" } ], "Newly Tracked": [ { "ticker": "NVS", "text": "Novartis", "url": "https://clearank.com/stock/novartis-nvs/" }, { "ticker": "AZN", "text": "AstraZeneca", "url": "https://clearank.com/stock/astrazeneca-azn/" }, { "ticker": "EUR/NZD", "text": "Euro / New Zealand Dollar", "url": "https://clearank.com/forex/eur-nzd/" }, { "ticker": "AUD/NZD", "text": "Australian Dollar / New Zealand Dollar", "url": "https://clearank.com/forex/aud-nzd/" }, { "ticker": "EUR/CAD", "text": "Euro / Canadian Dollar", "url": "https://clearank.com/forex/eur-cad/" } ], "Top Movers (24h)": [ { "ticker": "BBAI", "text": "↑ 10.85%", "url": "https://clearank.com/stock/bbai-stock-analysis/" }, { "ticker": "CRDO", "text": "↑ 10.77%", "url": "https://clearank.com/stock/credo-crdo/" }, { "ticker": "CIFR", "text": "↑ 9.86%", "url": "https://clearank.com/stock/cifr-stock-analysis/" }, { "ticker": "GLXY", "text": "↑ 9.57%", "url": "https://clearank.com/stock/galaxy-digital-glxy/" }, { "ticker": "UUUU", "text": "↑ 8.86%", "url": "https://clearank.com/stock/uuuu-stock-analysis/" } ], "Also in Healthcare": [ { "ticker": "MDT", "text": "Medtronic plc", "url": "https://clearank.com/stock/medtronic-mdt/" }, { "ticker": "NEOG", "text": "Neogen Corporation", "url": "https://clearank.com/stock/neogen-neog/" }, { "ticker": "OFIX", "text": "Orthofix Medical", "url": "https://clearank.com/stock/ofix-stock-analysis/" }, { "ticker": "QDEL", "text": "QuidelOrtho Corporation", "url": "https://clearank.com/stock/quidelortho-qdel/" }, { "ticker": "SYK", "text": "Stryker Corporation", "url": "https://clearank.com/stock/stryker-syk/" } ] }, "schema": [ { "@context": "https://schema.org", "@graph": [ { "@type": "Place", "@id": "https://clearank.com/#place", "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" } }, { "@type": "Organization", "@id": "https://clearank.com/#organization", "name": "CleaRank", "alternateName": "CleaRank Financial AI", "url": "https://clearank.com", "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), with a 7-day free trial, which combines a trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.", "slogan": "Clear data. Honest analysis.", "logo": { "@type": "ImageObject", "@id": "https://clearank.com/#logo", "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "caption": "CleaRank", "inLanguage": "en-US", "width": "336", "height": "153" }, "image": { "@id": "https://clearank.com/#logo" }, "sameAs": [ "https://x.com/CleaRank", "https://www.linkedin.com/company/clearank/", "https://www.youtube.com/@CleaRank", "https://t.me/clearank" ], "email": "info@clearank.com", "contactPoint": [ { "@type": "ContactPoint", "contactType": "customer support", "email": "info@clearank.com", "url": "https://clearank.com/contact/", "availableLanguage": "en" } ], "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" }, "location": { "@id": "https://clearank.com/#place" }, "knowsAbout": [ "stock analysis", "ETF analysis", "cryptocurrency analysis", "forex trading", "trading simulation", "trade journaling", "position sizing", "risk management", "prop firm challenges", "online broker regulation" ], "publishingPrinciples": "https://clearank.com/editorial-code/", "ethicsPolicy": "https://clearank.com/editorial-code/", "ownershipFundingInfo": "https://clearank.com/about-us/", "owns": { "@id": "https://clearank.com/#app" }, "founder": { "@id": "https://clearank.com/writer/shaundavidb/#person" } }, { "@type": "WebSite", "@id": "https://clearank.com/#website", "url": "https://clearank.com", "name": "CleaRank", "publisher": { "@id": "https://clearank.com/#organization" }, "inLanguage": "en-US" }, { "@type": "ImageObject", "@id": "https://clearank.com/og/mi/stock/zimmer-biomet-zbh.png", "url": "https://clearank.com/og/mi/stock/zimmer-biomet-zbh.png", "width": "1200", "height": "630", "caption": "Zimmer Biomet Holdings Inc. (ZBH) analysis by CleaRank", "inLanguage": "en-US" }, { "@type": "BreadcrumbList", "@id": "https://clearank.com/stock/zimmer-biomet-zbh/#breadcrumb", "itemListElement": [ { "@type": "ListItem", "position": 1, "item": { "@id": "https://clearank.com", "name": "Home" } }, { "@type": "ListItem", "position": 2, "item": { "@id": "https://clearank.com/stock/", "name": "Stocks" } }, { "@type": "ListItem", "position": 3, "item": { "@id": "https://clearank.com/stock/zimmer-biomet-zbh/", "name": "Zimmer Biomet Holdings Inc. (ZBH)" } } ] }, { "@type": "WebPage", "@id": "https://clearank.com/stock/zimmer-biomet-zbh/#webpage", "url": "https://clearank.com/stock/zimmer-biomet-zbh/", "name": "Zimmer Biomet (ZBH) Stock Forecast & Price Target (2026)", "datePublished": "2026-10-25T15:17:48+00:00", "dateModified": "2026-10-27T20:57:08+00:00", "isPartOf": { "@id": "https://clearank.com/#website" }, "primaryImageOfPage": { "@id": "https://clearank.com/og/mi/stock/zimmer-biomet-zbh.png" }, "inLanguage": "en-US", "breadcrumb": { "@id": "https://clearank.com/stock/zimmer-biomet-zbh/#breadcrumb" }, "reviewedBy": { "@id": "https://clearank.com/writer/jacob-bakshi/#person" } }, { "@type": "Person", "@id": "https://clearank.com/writer/jacob-bakshi/#person", "name": "Jacob Bakshi", "jobTitle": "Senior Market Strategist", "url": "https://clearank.com/writer/jacob-bakshi/", "worksFor": { "@id": "https://clearank.com/#organization" } }, { "@type": "Article", "@id": "https://clearank.com/stock/zimmer-biomet-zbh/#richSnippet", "headline": "Zimmer Biomet (ZBH) Stock Forecast & Price Target (2026)", "name": "Zimmer Biomet (ZBH) Stock Forecast & Price Target (2026)", "description": "ZBH stock forecast 2026: is Zimmer Biomet a buy? Analysts' median price target is $105 (9% upside). CleaRank Financial AI rates it Buy, 70/100. Updated daily.", "datePublished": "2026-10-25T15:17:48+00:00", "dateModified": "2026-10-27T20:57:08+00:00", "author": { "@id": "https://clearank.com/#organization" }, "publisher": { "@id": "https://clearank.com/#organization" }, "publishingPrinciples": "https://clearank.com/market-insights/methodology/", "about": { "@type": "Corporation", "name": "Zimmer Biomet Holdings Inc.", "identifier": [ { "@type": "PropertyValue", "propertyID": "tickerSymbol", "value": "ZBH" }, { "@type": "PropertyValue", "propertyID": "exchange", "value": "NYSE" } ], "description": "Zimmer Biomet Holdings Inc. is a global medical technology company focused on musculoskeletal healthcare. The company designs, manufactures, and markets orthopedic reconstructive products, including knee and hip systems, along with sports medicine, biologics, extremities, and trauma solutions. Its p", "tickerSymbol": "ZBH", "sameAs": "https://www.zimmerbiomet.com" }, "isPartOf": { "@id": "https://clearank.com/stock/zimmer-biomet-zbh/#webpage" }, "image": { "@id": "https://clearank.com/og/mi/stock/zimmer-biomet-zbh.png" }, "inLanguage": "en-US", "mainEntityOfPage": { "@id": "https://clearank.com/stock/zimmer-biomet-zbh/#webpage" } } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Is Zimmer Biomet Holdings Inc. (ZBH) a buy right now?", "acceptedAnswer": { "@type": "Answer", "text": "A score of 70/100 gives ZBH its Buy rating. Valuation carries the score: the P/E of 22.40 is 29.8% below the sector median (a discount to peers) and the P/S of 2.15 is 36.8% below the sector median. Revenue growth holds the score back, because revenue grew 4.80%, 3.3 percentage points slower than the sector median. This describes the data on this page and is not a personal recommendation." } }, { "@type": "Question", "name": "How has Zimmer Biomet Holdings Inc. (ZBH) performed over the past year?", "acceptedAnswer": { "@type": "Answer", "text": "Over the past year the price fell 6.83%. Over shorter periods it rose 0.34% in three months and rose 5.54% in the past month. It now trades 7.35% below its 52-week high of $103.70." } }, { "@type": "Question", "name": "What are the key price levels for ZBH?", "acceptedAnswer": { "@type": "Answer", "text": "The nearest level above the price is the 52-week high at $103.70. Going down, the first supports are the 50-day SMA at $95.06 and the 20-day EMA at $94.48." } }, { "@type": "Question", "name": "Is ZBH expensive compared with Healthcare stocks?", "acceptedAnswer": { "@type": "Answer", "text": "ZBH's trailing P/E of 22.40 is 29.8% below the Healthcare median of 31.9, a level the peer comparison on this page labels a discount to peers. Its price-to-sales ratio of 2.15 is 36.8% below the sector median of 3.4. These medians are drawn from 44 stocks across the entire sector, not just direct competitors." } }, { "@type": "Question", "name": "Does ZBH pay a dividend?", "acceptedAnswer": { "@type": "Answer", "text": "It does. ZBH pays a trailing dividend yield of 1.00%, which works out to $0.96 per share each year. Yield is calculated by dividing the dividend by the share price, so it moves whenever either of those moves." } }, { "@type": "Question", "name": "What do Wall Street analysts think of ZBH?", "acceptedAnswer": { "@type": "Answer", "text": "Of the 27 analysts covering ZBH, 8 rate it a buy, 19 rate it a hold, and none rate it a sell. Their median 12-month price target is $105.00, which is 9.3% above the current price." } }, { "@type": "Question", "name": "How often has ZBH beaten earnings estimates?", "acceptedAnswer": { "@type": "Answer", "text": "ZBH beat the EPS estimate in 6 of the 7 reports in our data; the share price fell in the first session after 3 of those 6 beats." } }, { "@type": "Question", "name": "How volatile is ZBH?", "acceptedAnswer": { "@type": "Answer", "text": "On an average day, ZBH's price moves 1.83%, based on the 30-day standard deviation of daily returns. Its beta against the S&P 500 is 0.49." } }, { "@type": "Question", "name": "Are ZBH insiders buying or selling?", "acceptedAnswer": { "@type": "Answer", "text": "Across the last 18 months, insiders unloaded $2.2M of shares and made no open-market purchases. Such sales are often arranged beforehand or tied to tax due on vesting shares, which makes them less telling than purchases." } }, { "@type": "Question", "name": "What is the 52-week range of ZBH?", "acceptedAnswer": { "@type": "Answer", "text": "Over the past 52 weeks, ZBH has moved between $79.12 and $103.70. At $96.08, the stock sits at 69% of that range, 21.44% above the low and 7.35% below the high." } } ] } ] }